Influenza Virus Patents (Class 424/206.1)
  • Patent number: 11147869
    Abstract: The present application relates to the field of human immunology, in particular, a herpes simplex virus (HSV) vaccine. The subunit vaccine composition comprises isolated surface glycoproteins from herpes simplex viruses, fusion proteins or fragments thereof mixed in varied combination with a nanoemulsion, which is a potent immune enhancer.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: October 19, 2021
    Assignee: BlueWillow Biologics, Inc.
    Inventors: Ali I. Fattom, Jakub Simon, James R. Baker, Jr., Tarek Hamouda, Vira Bitko
  • Patent number: 11046934
    Abstract: The disclosure provides for an isolated recombinant influenza virus having at least one of: a PA gene segment encoding PA with a residue at position 443 that is not arginine, a PB1 gene segment encoding PB1 with a residue at position 737 that is not lysine, a PB2 gene segment encoding PB2 with a residue at position 25 that is not valine or a residue at position 712 that is not glutamic acid, a NS gene segment encoding a NS1 with a residue at position 167 that is not proline, a HA gene segment encoding a HA with a residue at position 380 that is not threonine, or any combination thereof, and methods of making and using the virus.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: June 29, 2021
    Assignee: Wisconsin Alumni Research Foundation (WARF)
    Inventors: Yoshihiro Kawaoka, Satoshi Fukuyama, Shinji Watanabe
  • Patent number: 11020470
    Abstract: Provided herein are membrane enveloped virus-like particles (VLPs), and methods of use and synthesis thereof. In particular, yeast-cell-derived VLPs are provided that comprise surface-displayed glycoproteins and/or multiple virally-derived proteins.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: June 1, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Fei Wen, Eshita Khera, Brett Dallas Hill, Syed Rizvi
  • Patent number: 10973903
    Abstract: The present invention relates to compositions and methods for the treatment and prevention of canine influenza virus (CIV) and CIV-related pathology. The present invention is based on the development of mutant CIV, having one or more mutations in segment 8, which induces a CIV-specific immune response in a subject.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: April 13, 2021
    Assignees: University of Rochester, Cornell University
    Inventors: Luis Martinez-Sobrido, Aitor Nogales-Gonzalez, Colin Parrish
  • Patent number: 10953086
    Abstract: Disclosed is a universal influenza vaccine composition and corresponding methods comprising at least one attenuated live-attenuated influenza vaccine. The vaccine composition can exhibit a cross-protective effect against a wide range of influenza viruses and can ensure a strong protection efficacy, a wide range of protection, and safety. In addition, a vaccination method of heterologous live vaccines of the present invention induces various immunological effects so that cross-immunogenicity and cross-protective ability are remarkably increased, and thus is expected to be usefully utilized as a universal influenza prevention method. A person who has a basal immunity through infection with an influenza virus or vaccination with an influenza vaccine can be regarded as being in a state where primary vaccination has already been performed, single vaccination with a live vaccine induces an enhanced cross-immune response, and thus it is possible to expect a wide range of protective effects against various viruses.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: March 23, 2021
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Baik Lin Seong, Yo Han Jang, Young Ho Byun
  • Patent number: 10942181
    Abstract: The present disclosure provides a method for quantifying a vaccine. The method includes the steps of: 1) providing a plurality of standard mixtures, each of the standard mixtures having a standard antigen and an aluminum based adjuvant; 2) mixing a stabilizing solution with the vaccine and each of the standard mixtures; 3) determining dosages of the standard antigens in the standard mixtures to establish a standard curve; and 4) determining a dosage of a target antigen in the vaccine according to the standard curve.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: March 9, 2021
    Assignee: Adimmune Corporation
    Inventors: Juine-Ruey Chen, Chia-Ying Wu, Yung-Tsung Chen
  • Patent number: 10905756
    Abstract: The present invention relates to an immunogenic composition comprising: a) a modified live H3 virus of swine influenza, and b) a modified live H1 virus of swine influenza. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by swine influenza virus in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: February 2, 2021
    Inventors: Marc Allan Eichmeyer, Wesley Scott Johnson, Eric Martin Vaughn, Michelle L. Walz
  • Patent number: 10857228
    Abstract: The present invention provides an adjuvant for vaccine including a Dectin-1 ligand and a TLR agonist, a vaccine including the adjuvant for vaccine and at least one antigen, and the like.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: December 8, 2020
    Assignee: The University of Tokyo
    Inventors: Satoshi Uematsu, Naoki Takemura
  • Patent number: 10772950
    Abstract: The present invention relates to an immunogenic composition comprising: a) a modified live H3 virus of swine influenza, and b) a modified live H1 virus of swine influenza. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by swine influenza virus in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: September 15, 2020
    Inventors: Marc Allan Eichmeyer, Wesley Scott Johnson, Eric Martin Vaughn, Michelle L. Walz
  • Patent number: 10624961
    Abstract: Methods and uses are provided for inducing an immune response comprising at least two administrations of an immunogenic composition, wherein a lower dose is given in the second administration than in the first administration, and wherein the second administration may be unadjuvanted.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: April 21, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: William Ripley Ballou, Jr., Arnaud Michel Didierlaurent, Robbert Gerrit Van Der Most
  • Patent number: 10596206
    Abstract: Provided herein are probiotic compositions and methods to enhance bacterial diversity in the intestinal tract of a subject. A probiotic is provided comprising lymphoid tissue-resident commensal bacteria, and optionally IL-10, IL-22, and/or hepcidin. The probiotic can be used to promote intestinal health or to treat or prevent intestinal disease or condition.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: March 24, 2020
    Assignee: Cornell University
    Inventors: Gregory F. Sonnenberg, Nicholas J. Bessman
  • Patent number: 10562940
    Abstract: Described herein is the generation of optimized H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H1N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on selected H1N1 viruses isolated from 1918-2011. Provided herein are optimized H1N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: February 18, 2020
    Assignee: University of Pittsburgh— Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Corey J. Crevar
  • Patent number: 10555998
    Abstract: The present invention relates to equine influenza virus (EIV) isolates that when administered in vaccines to equine provide protection against currently emerging EIV strains in the U.S. The present invention also relates to inactivated EIV isolates. In addition, the present invention also relates to safe and efficacious vaccines that comprise the EIV isolates, as well as to corresponding subunit vaccines. The present invention further relates to methods of administering such safe and efficacious vaccines to equine.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: February 11, 2020
    Assignee: Intervet Inc.
    Inventors: Zhisong Qiao, Catherine M. Peters, Zhuyan Guo, Wendy Vaala, Craig Barnett
  • Patent number: 10463615
    Abstract: An improved method for the manufacture of an oil-in-water emulsion involves circulation of emulsion components between a first container and a second container via a homogenizer and/or via a microfluidization device. Usefully, all of the emulsion components from the first container are emptied before being returned.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: November 5, 2019
    Assignee: NOVARTIS AG
    Inventors: Harald Rueckl, Hanno Scheffczik, Barbara Santry
  • Patent number: 10369212
    Abstract: The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: August 6, 2019
    Assignee: Wisconsin Alumni Research Foundation (WARF)
    Inventors: Christopher W. Olsen, Gabriele A. Landolt, Alexander I. Karasin
  • Patent number: 10350286
    Abstract: The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: July 16, 2019
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Michel Bublot, Frederic Reynard, François-Xavier Le Gros
  • Patent number: 10226527
    Abstract: The present invention provides a system for analyzing interactions between glycans and interaction partners that bind to them. The present invention also provides HA polypeptides that bind to umbrella-topology glycans, and reagents and methods relating thereto.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: March 12, 2019
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Kannan Tharakaraman, Karthik Viswanathan, Rahul Raman, Ram Sasisekharan
  • Patent number: 10188732
    Abstract: Aspects of the invention provide therapeutic recombinant protein preparations and methods of preparing therapeutic recombinant protein, which methods include contacting recombinant protein preparations with zwitterionic detergent at or above critical micelle concentration of the detergent.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: January 29, 2019
    Assignee: Biogen MA Inc.
    Inventors: Lynn Edward Conley, Yinying Tao
  • Patent number: 10125374
    Abstract: The present invention provides a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein of at least 73 and up to 122 amino acids of the N-terminus of the respective wild type NS 1 protein, wherein said vector replicates in IFN-sensitive tumor cells and does not replicate in normal, non-tumor cells, and expresses a heterologous immunostimulatory polypetide. The invention further provides a pharmaceutical composition containing said influenza virus vector, its use for the treatment of cancer patients and methods for producing said influenza virus vaccine.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: November 13, 2018
    Assignee: BLUE SKY VACCINES GMBH
    Inventor: Thomas Muster
  • Patent number: 10105435
    Abstract: The invention provides compositions comprising liposomes, an antigen capable of inducing a humoral immune response, a carrier comprising a continuous phase of a hydrophobic substance, and an adjuvant that activates or increases the activity of TLR2. The invention also provides uses for such compositions in inducing a humoral response and methods for their use in the treatment of a disease, disorder or ailment ameliorated by a humoral immune response.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: October 23, 2018
    Assignee: IMMUNOVACCINE TECHNOLOGIES INC.
    Inventors: Marc Mansour, Lisa Diana MacDonald, Genevieve Mary Weir, Leeladhar Sammatur, Kendall Sharp
  • Patent number: 10034932
    Abstract: The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: July 31, 2018
    Assignee: Wisconsin Alumni Research Foundation (WARF)
    Inventors: Christopher W. Olsen, Gabriele A. Landolt, Alexander I. Karasin
  • Patent number: 10029005
    Abstract: The present invention relates to an immunogenic composition comprising: a) a modified live H3 virus of swine influenza, and b) a modified live H1 virus of swine influenza. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by swine influenza virus in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: July 24, 2018
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Marc Allan Eichmeyer, Wesley Scott Johnson, Eric Martin Vaughn, Michelle L. Walz
  • Patent number: 10030231
    Abstract: Improved methods for the production of reassortant influenza viruses are provided.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: July 24, 2018
    Assignees: Seqirus UK Limited, Synthetic Genomics Vaccines, Inc.
    Inventors: Philip Dormitzer, Peter Mason, Pirada Suphaphiphat, Daniel Gibson, David Wentworth, Timothy Stockwell, John Glass
  • Patent number: 9982240
    Abstract: The invention relates to a method for producing influenza infectious viruses wherein CHO cells are infected with a seed of infectious influenza virus which has been generated by transfecting cells with an appropriate set of expression vectors. The invention also relates to a recombination cassette, and to a vector comprising said recombination cassette, that may be used in methods for producing infectious viruses, and particularly in the method according to the invention.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: May 29, 2018
    Assignee: Sanofi Pasteur
    Inventors: Isabelle Legastelois, Julie Medina, Catherine Moste
  • Patent number: 9901630
    Abstract: An influenza vaccine is administered by a multi-dose regimen, in which (i) a first dose is administered with an adjuvant and (ii) a later dose is administered either without an adjuvant or with a different adjuvant. Thus the invention provides the benefits of a two-dose regimen without also doubling the supply need for a given adjuvant.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: February 27, 2018
    Assignee: Seqirus UK Limited
    Inventors: Giuseppe Del Giudice, Riccardo Manetti
  • Patent number: 9878034
    Abstract: The invention relates to adjuvanted vaccine formulations, in particular influenza vaccines for intranasal delivery. Provided is an adjuvanted influenza vaccine formulation, comprising (i) peptidoglycan microparticles obtained from a Gram-positive bacterium and (ii) at least one influenza virus antigen or antigenic preparation thereof, which antigen or antigenic preparation is not fused or otherwise covalently attached to a proteinaceous peptidoglycan binding moiety.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: January 30, 2018
    Assignee: MUCOSIS B.V.
    Inventors: Govert Johan Schouten, Cornelis Johannes Leenhouts
  • Patent number: 9878032
    Abstract: Provided herein are attenuated influenza viruses and methods of making attenuated influenza viruses.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: January 30, 2018
    Assignee: UNIVERSITY OF ROCHESTER
    Inventors: Andrew Cox, Stephen Dewhurst, John Treanor, Baek Kim
  • Patent number: 9872900
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (NAVs) comprising polynucleotide molecules encoding one or more antigens.
    Type: Grant
    Filed: April 5, 2016
    Date of Patent: January 23, 2018
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Axel Bouchon, Eric Yi-Chun Huang
  • Patent number: 9827190
    Abstract: An intradermal delivery system comprises an immunogenic composition comprising a TLR agonist and immunogen and a microneedle. The immunogenic composition may comprise a solid biodegradable microneedle or a solid coated microneedle. The intradermal delivery system may be formulated into a skin patch.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: November 28, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Barbara Baudner, Simona Gallorini, Derek O'Hagan
  • Patent number: 9814770
    Abstract: The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: November 14, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Christopher W. Olsen, Gabriele A. Landolt, Alexander I. Karasin
  • Patent number: 9808517
    Abstract: The present invention relates to a probiotic cell transformed with a construct suitable to overexpress and display on the surface of the probiotic cell a fusion protein comprising at least a portion of a transport protein coupled to at least a portion of one or more antigenic proteins or peptides. Probiotic-derived vesicles displaying this fusion protein as well as methods of inducing an immune response using the probiotic cells or vesicles are also disclosed.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: November 7, 2017
    Assignee: Cornell University
    Inventors: David Putnam, Joseph Rosenthal, Chung-Jr Huang, Matthew Delisa, Susana Mendez
  • Patent number: 9771564
    Abstract: The present invention provides a novel influenza virus wherein both the NS and the PB1 gene segments are modified and wherein the PB1-F2 open reading frame is modified by introduction of at least one stop codon. Specifically, the influenza virus is lacking functional NS1 and PB1-F2 proteins. Additionally, a vaccine formulation comprising the modified influenza virus is provided and its use for prevention of influenza vaccination.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: September 26, 2017
    Assignee: NANOTHERAPEUTICS, INC.
    Inventors: Thomas Muster, Ekaterina Romanovskaya-Romanko, Oleg Kiselev, Markus Wolschek, Boris Ferko, Andrej Egorov
  • Patent number: 9580761
    Abstract: The present invention provides an internal positive control for contaminating viruses. The invention provides the use of a second virus as an exogenous internal positive control in methods for verifying the reliability of an assay to detect a first virus, in methods of ensuring the absence of the first virus in a biological sample or pharmaceutical sample and in methods of manufacturing a vaccine free from a first virus.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: February 28, 2017
    Assignee: Novartis AG
    Inventor: Bernhard Roth
  • Patent number: 9549970
    Abstract: The invention provides methods for culturing yeast at a neutral pH level. Yeast cultured under neutral pH conditions exhibit desirable characteristics useful for biological purposes, such as the development of vaccines, prophylactics and therapeutics. The invention also provides for compositions and kits comprising yeast grown using the methodologies disclosed herein.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: January 24, 2017
    Assignee: GlobeImmune, Inc.
    Inventors: Alex Franzusoff, Deborah Quick
  • Patent number: 9549975
    Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: January 24, 2017
    Assignees: Icahn School of Medicine at Mount Sinai, St. Jude Children's Research Hospital, The United States of America, as Represented by the Secretary of Agriculture
    Inventors: Peter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
  • Patent number: 9546936
    Abstract: In a method for processing biological materials for flow cytometry evaluation for virus particles, a mixture including biological material and purification particles is centrifuged to prepare a centrifuged composition including a supernatant that may be further processed prior to the flow cytometry evaluation. The purification particles include porous cores functionalized to capture smaller-size impurities in a biological material sample and a porous size-exclusion shell surrounding the core to exclude larger-size components of the biological material from entering into the core. Multiple samples may be processed in multi-sample processing units. A product may contain a sealed container with the unit quantity of purification particle in a storage liquid and a kit may include such a sealed container and a centrifugal filter.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: January 17, 2017
    Assignee: VIROCYT, INC.
    Inventors: Kathy L. Rowlen, Erica Dawson Tenent, Lauren R. Wolfe
  • Patent number: 9492530
    Abstract: The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: November 15, 2016
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Christopher W. Olsen, Gabriele A. Landolt, Alexander I. Karasin
  • Patent number: 9387240
    Abstract: The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: July 12, 2016
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Peter Palese, Adolfo Garcia-Sastre, Thomas Muster
  • Patent number: 9345758
    Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: May 24, 2016
    Assignees: University of Florida Research Foundation, Inc., The United States of America as represented by The Secretary of The Department of Health and Human Services, Centers for Disease Control and Prevention, Cornell Research Foundation, Inc.
    Inventors: Patti C. Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, William L. Castleman, Nancy J. Cox
  • Patent number: 9260486
    Abstract: The present invention relates to cGMP protein kinase (PKG) and regulatory domains and methods of use thereof. The structural determination of PKG domains is also described. cGMP independent PKG activators and uses thereof are also described.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: February 16, 2016
    Assignee: The University of Vermont and State Agricultural College
    Inventors: Wolfgang Dostmann, Brent W. Osborne, Thomas M. Moon
  • Patent number: 9254315
    Abstract: The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease including vaccines and therapeutics for emerging viral diseases and methods of identifying the new class of peptides and related structures.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: February 9, 2016
    Inventors: Samuel Bogoch, Elenore S. Bogoch, Samuel Winston Bogoch, Anne Elenore Borsanyi
  • Patent number: 9192660
    Abstract: Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotypes using the vaccines that are provided.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: November 24, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B Weiner, Matthew P Morrow, Jian Yan
  • Patent number: 9173933
    Abstract: The invention concerns a recombinant modified vaccinia virus Ankara (MVA virus) expressing at least two external influenza virus antigens and/or an epitope of one or more of the at least two antigens and at least two internal influenza virus antigens and/or an epitope of the at least two antigens. The invention, thus, concerns a recombinant MVA virus encoding multiple external and/or internal influenza virus antigens, preferably from multiple influenza virus strains. The invention further concerns the use of said recombinant MVA in preparing a medicament and vaccine for influenza virus. Further encompassed by the present invention are methods, composition and kits.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: November 3, 2015
    Assignee: BAVARIAN NORDIC A/S
    Inventors: Josef Weigl, Jürgen Hausmann, Robin Steigerwald
  • Patent number: 9163219
    Abstract: The present invention encompasses an expression vector that is capable of generating a virus from a segmented genome. In particular, a single expression vector may be utilized to produce influenza virus in cultured cells. The expression vector can be delivered in a purified DNA form or by a suitably designed bacterial carrier to cells in culture or to animals. This invention increases the virus generation efficiency, which benefits vaccine development. The bacterial carrier harboring such a plasmid encoding an attenuated virus may be used as a vaccine against corresponding viral disease.
    Type: Grant
    Filed: April 14, 2010
    Date of Patent: October 20, 2015
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Roy Curtiss, III, Xiangmin Zhang
  • Patent number: 9144606
    Abstract: The present invention relates to methods for inducing an immune response to influenza in a subject comprising administering a nanoemulsion vaccine composition comprising an influenza immunogen or protein.
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: September 29, 2015
    Assignee: NanoBio Corporation
    Inventors: James R. Baker, Jr., Tarek Hamouda, Joyce A. Sutcliffe
  • Patent number: 9028463
    Abstract: The present invention provides a method for enhancing the immunogenicity using a microneedle device capable of enhancing the immunogenicity of an influenza vaccine. According to the method for enhancing the immunogenicity using the present microneedle device, a microneedle device having microneedles made of polylactic acid, coated with an influenza vaccine composed of an antigen having type A strain (H1N1), type A strain (H3N2), and type B strain as active ingredients is brought into direct contact with the skin so as to transcutaneously administer the aforementioned influenza vaccine. After the transcutaneous administration, lauryl alcohol is applied to the site of the skin where the microneedle device has been brought into direct contact.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: May 12, 2015
    Assignees: Hisamitsu Pharmaceutical Co., Inc., The Chemo-Sero-Therapeutic Research Institute
    Inventors: Chikateru Nozaki, Kazuyoshi Kaminaka, Junichi Matsuda, Takaaki Terahara, Tetsuji Kuwahara, Seiji Tokumoto
  • Patent number: 9028838
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: May 12, 2015
    Assignee: MedImmune, LLC
    Inventors: Chin-Fen Yang, George Kemble
  • Patent number: 9017694
    Abstract: The technology relates in part to modified influenza viruses useful for vaccine development. Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: April 28, 2015
    Assignee: MedImmune, LLC
    Inventors: Hong Jin, Zhongying Chen
  • Patent number: 9011874
    Abstract: Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions. In other embodiments, vaccine compositions are reported of use in a subject.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: April 21, 2015
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Timothy D. Powell, Jeremy Jones
  • Patent number: RE45564
    Abstract: The present invention provides an isolated canine influenza virus of subtype H3N8 comprising an HA having SEQ ID NO: 4 or an amino acid sequence that is greater than 99% identical to SEQ ID NO: 4, with the proviso that the amino acids at positions 94 and 233 are identical to SEQ ID NO: 4; a composition comprising attenuated or inactivated virus; isolated or purified HA, NM, NP, M1, NS1, PA, PB1, and PB2 proteins and fragments thereof and compositions comprising same or nucleic acids, optionally as part of a vector, encoding same; and a method of inducing an immune response to canine influenza virus in an animal comprising administering to the animal an aforementioned composition.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: June 16, 2015
    Assignee: IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
    Inventors: Kyoung-Jin Yoon, Vickie Cooper